Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods

References

• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• LouisDNOhgakiHWiestlerODThe 2007 WHO classification of tumours of the central nervous systemActa Neuropathol200711429710917618441
   PubMed Web of Science ®Google Scholar
• OstromQTGittlemanHFarahPCBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States 2006–2010Neuro-Oncol201315sup 2ii1ii5624137015
   PubMedGoogle Scholar
• KleihuesPLouisDNScheithauerBWThe WHO classification of tumors of the nervous systemJ Neuropathol Exp Neurol2002613215225 discussion 226–22911895036
   PubMed Web of Science ®Google Scholar
• FisherJLSchwartzbaumJAWrenschMWiemelsJLEpidemiology of brain tumorsNeurol Clin2007254867890 vii17964019
   PubMed Web of Science ®Google Scholar
• Barnholtz-SloanJSSloanAEDavisFGVigneauFDLaiPSawayaREIncidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJ Clin Oncol200422142865287215254054
   PubMed Web of Science ®Google Scholar
• DavisFGDolecekTAMcCarthyBJVillanoJLToward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence dataNeuro Oncol20121491171117722898372
   PubMed Web of Science ®Google Scholar
• GuptaKSalunkePMolecular markers of glioma: an update on recent progress and perspectivesJ Cancer Res Clin Oncol2012138121971198123052697
   PubMed Web of Science ®Google Scholar
• OlarAAldapeKDBiomarkers classification and therapeutic decision-making for malignant gliomasCurr Treat Options Oncol201213441743622956341
   PubMed Web of Science ®Google Scholar
• ClarkKHVillanoJLNikiforovaMNHamiltonRLHorbinskiC1p/19q testing has no significance in the workup of glioblastomasNeuropathol Appl Neurobiol201339670671723363074
   PubMed Web of Science ®Google Scholar
• CairncrossGWangMShawEPhase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402J Clin Oncol201331333734323071247
   PubMed Web of Science ®Google Scholar
• LassmanABSuccess at last: a molecular factor that informs treatmentCurr Oncol Rep2013151475523247800
   PubMed Web of Science ®Google Scholar
• van den BentMJBrandesAATaphoornMJAdjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951J Clin Oncol201331334435023071237
   PubMed Web of Science ®Google Scholar
• BelloMJde CamposJMKusakMEAllelic loss at 1p is associated with tumor progression of meningiomasGenes Chromosomes Cancer1994942962987519053
   PubMed Web of Science ®Google Scholar
• ReifenbergerJReifenbergerGLiuLJamesCDWechslerWCollinsVPMolecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1pAm J Pathol19941455117511907977648
   PubMed Web of Science ®Google Scholar
• IchimuraKMolecular pathogenesis of IDH mutations in gliomasBrain Tumor Pathol201229313113922399191
   PubMed Web of Science ®Google Scholar
• HartmannCHentschelBWickWPatients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomasActa Neuropathol2010120670771821088844
   PubMed Web of Science ®Google Scholar
• OlsonRABrastianosPKPalmaDAPrognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysisJ Neurooncol2011105232533521523485
   PubMed Web of Science ®Google Scholar
• HegiMEDiserensACGorliaTMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med200535210997100315758010
   PubMed Web of Science ®Google Scholar
• BrandesAAFranceschiETosoniAMGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patientsJ Clin Oncol200826132192219718445844
   PubMed Web of Science ®Google Scholar
• OhgakiHKleihuesPGenetic pathways to primary and secondary glioblastomaAm J Pathol200717051445145317456751
   PubMed Web of Science ®Google Scholar
• OlarARaghunathanAAlbarracinCTAbsence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adultsAnn Diagn Pathol201216316117022197544
   PubMed Web of Science ®Google Scholar
• VerhaakRGHoadleyKAPurdomECancer Genome Atlas Research NetworkIntegrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell20101719811020129251
   PubMed Web of Science ®Google Scholar
• PhillipsHSKharbandaSChenRMolecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesisCancer Cell20069315717316530701
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature200845572161061106818772890
   PubMed Web of Science ®Google Scholar
• NoushmehrHWeisenbergerDJDiefesKCancer Genome Atlas Research NetworkIdentification of a CpG island methylator phenotype that defines a distinct subgroup of gliomaCancer Cell201017551052220399149
   PubMed Web of Science ®Google Scholar
• GanHKKayeAHLuworRBThe EGFRvIII variant in glioblastoma multiformeJ Clin Neurosci200916674875419324552
   PubMed Web of Science ®Google Scholar
• MellinghoffIKSchultzNMischelPSCloughesyTFWill kinase inhibitors make it as glioblastoma drugs?Curr Top Microbiol Immunol201235513516922015553
   PubMed Web of Science ®Google Scholar
• MellinghoffIKCloughesyTFMischelPSPTEN-mediated resistance to epidermal growth factor receptor kinase inhibitorsClin Cancer Res2007132 Pt 137838117255257
   PubMed Web of Science ®Google Scholar
• KimYHNonoguchiNPaulusWFrequent BRAF gain in low-grade diffuse gliomas with 1p/19q lossBrain Pathol201222683484022568401
   PubMed Web of Science ®Google Scholar
• SalamaAKFlahertyKTBRAF in Melanoma: Current strategies and future directionsClin Cancer Res201319164326433423770823
   PubMed Web of Science ®Google Scholar
• Hoang-XuanKCapelleLKujasMTemozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletionsJ Clin Oncol200422153133313815284265
   PubMed Web of Science ®Google Scholar
• HegiMELiuLHermanJGCorrelation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activityJ Clin Oncol200826254189419918757334
   PubMed Web of Science ®Google Scholar
• Haas-KoganDAPradosMDTihanTEpidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinibJ Natl Cancer Inst2005971288088715956649
   PubMed Web of Science ®Google Scholar
• MellinghoffIKWangMYVivancoIMolecular determinants of the response of glioblastomas to EGFR kinase inhibitorsN Engl J Med2005353192012202416282176
   PubMed Web of Science ®Google Scholar
• RichJNReardonDAPeeryTPhase II trial of gefitinib in recurrent glioblastomaJ Clin Oncol200422113314214638850
   PubMed Web of Science ®Google Scholar
• KienastYvon BaumgartenLFuhrmannMReal-time imaging reveals the single steps of brain metastasis formationNat Med201016111612220023634
   PubMed Web of Science ®Google Scholar
• SeikeTFujitaKYamakawaYInteraction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasisClin Exp Metastasis2011281132520953899
   PubMed Web of Science ®Google Scholar
• StemmlerHJKahlertSSiekieraWUntchMHeinrichBHeinemannVCharacteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancerBreast200615221922516026983
   PubMed Web of Science ®Google Scholar
• MillerKDWeathersTHaneyLGOccult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survivalAnn Oncol20031471072107712853349
   PubMed Web of Science ®Google Scholar
• GabosZSinhaRHansonJPrognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancerJ Clin Oncol200624365658566317102066
   PubMed Web of Science ®Google Scholar
• LinNUBellonJRWinerEPCNS metastases in breast cancerJ Clin Oncol200422173608361715337811
   PubMed Web of Science ®Google Scholar
• CleversHNusseRWnt/beta-catenin signaling and diseaseCell201214961192120522682243
   PubMed Web of Science ®Google Scholar
• NguyenDXBosPDMassaguéJMetastasis: from dissemination to organ-specific colonizationNat Rev Cancer20099427428419308067
   PubMed Web of Science ®Google Scholar
• KellyPJDaumas-DuportCScheithauerBWKallBAKispertDBStereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasmsMayo Clin Proc19876264504593553757
   PubMed Web of Science ®Google Scholar
• EarnestF4thKellyPJScheithauerBWCerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsyRadiology198816638238272829270
   PubMed Web of Science ®Google Scholar
• BucknerJCBrownPDO’NeillBPMeyerFBWetmoreCJUhmJHCentral nervous system tumorsMayo Clin Proc200782101271128617908533
   PubMed Web of Science ®Google Scholar
• GrantRLiangBCSlatteryJGreenbergHSJunckLChemotherapy response criteria in malignant gliomaNeurology1997485133613409153469
   PubMed Web of Science ®Google Scholar
• WilmsGMarchalGDemaerelPHVan HeckePBaertALGadolinium-enhanced MRI of intracranial lesions. A review of indications and resultsClin Imaging19911531531651933642
   PubMed Web of Science ®Google Scholar
• ValkPEDillonWPRadiation-Injury of the Brain. Am J RoentgenolApr19911564689706
   Google Scholar
• MountzJMDeutschGKuznieckyRRosenfeldSSBrain SPECT 1994 updateFreemanLMNuclear medicine annual 1994New YorkRaven Press1994154
   Google Scholar
• SchwartzRBHolmanBLPolakJFDual-isotope single-photon emission computerized tomography scanning in patients with glioblastoma multiforme: association with patient survival and histopathological characteristics of tumor after high-dose radiotherapyJ Neurosurg199889160689647173
   PubMed Web of Science ®Google Scholar
• KaplanWDTakvorianTMorrisJHRumbaughCLConnollyBTAtkinsHLThallium-201 brain tumor imaging: a comparative study with pathologic correlationJ Nucl Med198728147523467030
   PubMed Web of Science ®Google Scholar
• BlackKLHawkinsRAKimKTBeckerDPLernerCMarcianoDUse of thallium-201 SPECT to quantitate malignancy grade of gliomasJ Neurosurg19897133423462549223
   PubMed Web of Science ®Google Scholar
• WenPYMacdonaldDRReardonDAUpdated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working groupJ Clin Oncol201028111963197220231676
   PubMed Web of Science ®Google Scholar
• OborskiMJLaymonCMLiebermanFSMountzJMDistinguishing pseudoprogression from progression in high-grade gliomas: a brief review of current clinical practice and demonstration of the potential value of 18F-FDG PETClin Nucl Med201338538138423510887
   PubMed Web of Science ®Google Scholar
• ShahAHSnellingBBregyADiscriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?J Neurooncol2013112214115223344789
   PubMed Web of Science ®Google Scholar
• ChaSUpdate on brain tumor imaging: from anatomy to physiologyAJNR Am J Neuroradiol200627347548716551981
   PubMed Web of Science ®Google Scholar
• YoungGSAdvanced MRI of adult brain tumorsNeurol Clin200725494797317964022
   PubMed Web of Science ®Google Scholar
• LevivierMBecerraADe WitteOBrotchiJGoldmanSRadiation necrosis or recurrenceJ Neurosurg19968411481498613825
   PubMed Web of Science ®Google Scholar
• Del SoleAFaliniARavasiLAnatomical and biochemical investigation of primary brain tumoursEur J Nucl Med200128121851187211734927
   PubMedGoogle Scholar
• GinsbergLEFullerGNHashmiMLeedsNESchomerDFThe significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a seriesSurg Neurol19984944364409537664
   PubMedGoogle Scholar
• ScottJNBrasherPMSevickRJRewcastleNBForsythPAHow often are nonenhancing supratentorial gliomas malignant? A population studyNeurology200259694794912297589
   PubMed Web of Science ®Google Scholar
• van den BentMJVogelbaumMAWenPYMacdonaldDRChangSMEnd point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s CriteriaJ Clin Oncol200927182905290819451418
   PubMed Web of Science ®Google Scholar
• TaalWBrandsmaDde BruinHGIncidence of early pseudoprogression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomideCancer2008113240541018484594
   PubMed Web of Science ®Google Scholar
• HamstraDAGalbánCJMeyerCRFunctional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survivalJ Clin Oncol200826203387339418541899
   PubMed Web of Science ®Google Scholar
• HamstraDAChenevertTLMoffatBAEvaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade gliomaProc Natl Acad Sci U S A200510246167591676416267128
   PubMed Web of Science ®Google Scholar
• NowosielskiMRecheisWGoebelGADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade gliomaNeuroradiology201153429130221125399
   PubMed Web of Science ®Google Scholar
• PopeWBKimHJHuoJRecurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatmentRadiology2009252118218919561256
   PubMed Web of Science ®Google Scholar
• NordenADYoungGSSetayeshKBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology2008701077978718316689
   PubMed Web of Science ®Google Scholar
• CastilloMKwockLMukherjiSKClinical applications of proton MR spectroscopyAJNR Am J Neuroradiol19961711158770242
   PubMed Web of Science ®Google Scholar
• MillerBLA review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and cholineNMR Biomed19914247521650241
   PubMed Web of Science ®Google Scholar
• CastilloMKwockLScatliffJMukherjiSKProton MR spectroscopy in neoplastic and non-neoplastic brain disordersMagn Reson Imaging Clin N Am1998611209449737
   PubMedGoogle Scholar
• MichaelisTMerboldtKDBruhnHHänickeWFrahmJAbsolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectraRadiology199318712192278451417
   PubMed Web of Science ®Google Scholar
• HerminghausSPilatusUMöller-HartmannWIncreased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumorsNMR Biomed200215638539212357552
   PubMed Web of Science ®Google Scholar
• KreisRErnstTRossBDDevelopment of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopyMagn Reson Med19933044244378255190
   PubMed Web of Science ®Google Scholar
• LiXLuYPirzkallAMcKnightTNelsonSJAnalysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patientsJ Magn Reson Imaging200216322923712205577
   PubMed Web of Science ®Google Scholar
• HattingenEDelicOFranzK(1)H MRSI and progression-free survival in patients with WHO grades II and III gliomasNeurol Res201032659360219726017
   PubMed Web of Science ®Google Scholar
• HattingenERaabPFranzKPrognostic value of choline and creatine in WHO grade II gliomasNeuroradiology200850975976718523762
   PubMed Web of Science ®Google Scholar
• ImaniFBoadaFELiebermanFSDavisDKDeebELMountzJMComparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progressionJ Neuroimaging201222218419021155917
   PubMed Web of Science ®Google Scholar
• ElkhaledAJalbertLEPhillipsJJMagnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomasSci Transl Med20124116116ra5
   PubMed Web of Science ®Google Scholar
• KalininaJCarrollAWangLDetection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in gliomaJ Mol Med (Berl)201290101161117122426639
   PubMed Web of Science ®Google Scholar
• PopeWBPrinsRMAlbert ThomasMNon-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopyJ Neurooncol2012107119720522015945
   PubMed Web of Science ®Google Scholar
• Le BihanDMolecular diffusion, tissue microdynamics and microstructureNMR Biomed199587–83753868739274
   PubMed Web of Science ®Google Scholar
• ArvindaHRKesavadasCSarmaPSGlioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imagingJ Neurooncol2009941879619229590
   PubMed Web of Science ®Google Scholar
• JensenJHHelpernJAMRI quantification of non-Gaussian water diffusion by kurtosis analysisNMR Biomed201023769871020632416
   PubMed Web of Science ®Google Scholar
• RaabPHattingenEFranzKZanellaFELanfermannHCerebral gliomas: diffusional kurtosis imaging analysis of microstructural differencesRadiology2010254387688120089718
   PubMed Web of Science ®Google Scholar
• ChaSKnoppEAJohnsonGWetzelSGLittAWZagzagDIntracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imagingRadiology20022231112911930044
   PubMed Web of Science ®Google Scholar
• BoxermanJLSchmaindaKMWeisskoffRMRelative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do notAJNR Am J Neuroradiol200627485986716611779
   PubMed Web of Science ®Google Scholar
• HuLSBaxterLCPinnaduwageDSOptimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomasAJNR Am J Neuroradiol2010311404819749223
   PubMed Web of Science ®Google Scholar
• LawMYangSWangHGlioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imagingAJNR Am J Neuroradiol200324101989199814625221
   PubMed Web of Science ®Google Scholar
• ProvenzaleJMYorkGMoyaMGCorrelation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasmsAJR Am J Roentgenol200618741036104216985154
   PubMed Web of Science ®Google Scholar
• RobertsCIssaBStoneAJacksonAWatertonJCParkerGJComparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studiesJ Magn Reson Imaging200623455456316506143
   PubMed Web of Science ®Google Scholar
• SpampinatoMVSmithJKKwockLCerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumorsAJR Am J Roentgenol2007188120421217179366
   PubMed Web of Science ®Google Scholar
• DanchaivijitrNWaldmanADTozerDJLow-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation?Radiology2008247117017818372467
   PubMed Web of Science ®Google Scholar
• WarburgOOn the origin of cancer cellsScience1956123319130931413298683
   PubMed Web of Science ®Google Scholar
• KrohnKAMankoffDAMuziMLinkJMSpenceAMTrue tracers: comparing FDG with glucose and FLT with thymidineNucl Med Biol200532766367116243640
   PubMed Web of Science ®Google Scholar
• PadmaMVSaidSJacobsMPrediction of pathology and survival by FDG PET in gliomasJ Neurooncol200364322723714558598
   PubMed Web of Science ®Google Scholar
• De WitteOLevivierMViolonPPrognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade gliomaNeurosurgery1996393470476 discussion 476–4778875476
   PubMed Web of Science ®Google Scholar
• DelbekeDMeyerowitzCLapidusRLOptimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PETRadiology1995195147527892494
   PubMed Web of Science ®Google Scholar
• SpenceAMMuziMMankoffDA18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matterJ Nucl Med200445101653165915471829
   PubMed Web of Science ®Google Scholar
• WongTZvan der WesthuizenGJColemanREPositron emission tomography imaging of brain tumorsNeuroimaging Clin N Am200212461562612687915
   PubMed Web of Science ®Google Scholar
• WürkerMHerholzKVogesJGlucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapyEur J Nucl Med19962355835868698067
   PubMedGoogle Scholar
• RicciPEKarisJPHeisermanJEFramEKBiceANDrayerBPDifferentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?AJNR Am J Neuroradiol19981934074139541290
   PubMed Web of Science ®Google Scholar
• LanglebenDDSegallGMPET in differentiation of recurrent brain tumor from radiation injuryJ Nucl Med200041111861186711079496
   PubMed Web of Science ®Google Scholar
• FranceschiETosoniABartoliniSMazzocchiVFioravantiABrandesAATreatment options for recurrent glioblastoma: pitfalls and future trendsExpert Rev Anticancer Ther20099561361919445578
   PubMed Web of Science ®Google Scholar
• MacdonaldDRCascinoTLScholdSCJrCairncrossJGResponse criteria for phase II studies of supratentorial malignant gliomaJ Clin Oncol199087127712802358840
   PubMed Web of Science ®Google Scholar
• EstellerMGarcia-FoncillasJAndionEInactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agentsN Engl J Med2000343191350135411070098
   PubMed Web of Science ®Google Scholar
• BrandesAATosoniACavalloGGICNOCorrelations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO studyJ Clin Oncol200624294746475316954518
   PubMed Web of Science ®Google Scholar
• ClarkeJLChangSPseudoprogression and pseudoresponse: challenges in brain tumor imagingCurr Neurol Neurosci Rep20099324124619348713
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res20071341253125917317837
   PubMed Web of Science ®Google Scholar
• BatchelorTTSorensenAGdi TomasoEAZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsCancer Cell2007111839517222792
   PubMed Web of Science ®Google Scholar
• DesjardinsAReardonDAHerndonJE2ndBevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomasClin Cancer Res200814217068707318981004
   PubMed Web of Science ®Google Scholar
• ChaoSTSuhJHRajaSLeeSYBarnettGThe sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgeryInt J Cancer200196319119711410888
   PubMed Web of Science ®Google Scholar
• WangSXBoethiusJEricsonKFDG-PET on irradiated brain tumor: ten years’ summaryActa Radiol2006471859016498938
   PubMed Web of Science ®Google Scholar
• SchlemmerHPPichlerBJSchmandMSimultaneous MR/PET imaging of the human brain: feasibility studyRadiology200824831028103518710991
   PubMed Web of Science ®Google Scholar
• BossABisdasSKolbAHybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CTJ Nucl Med20105181198120520660388
   PubMed Web of Science ®Google Scholar
• TanakaYNariaiTMomoseTGlioma surgery using a multimodal navigation system with integrated metabolic imagesJ Neurosurg2009110116317218847337
   PubMed Web of Science ®Google Scholar
• GrosuALWeberWARiedelEL-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapyInt J Radiat Oncol Biol Phys2005631647416111573
   PubMed Web of Science ®Google Scholar
• WeberDCZilliTBucheggerF[(18)F]Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade gliomaRadiat Oncol200834419108742
   PubMed Web of Science ®Google Scholar
• VeesHSenthamizhchelvanSMiralbellRWeberDCRatibOZaidiHAssessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patientsEur J Nucl Med Mol Imaging200936218219318818918
   PubMed Web of Science ®Google Scholar
• NariaiTTanakaYWakimotoHUsefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of gliomaJ Neurosurg2005103349850716235683
   PubMed Web of Science ®Google Scholar
• BuschHDavisJRHonigGRAndersonDCNairPVNyhanWLThe uptake of a variety of amino acids into nuclear proteins of tumors and other tissuesCancer Res1959191030103913806375
   PubMed Web of Science ®Google Scholar
• MiyagawaTOkuTUeharaH“Facilitated” amino acid transport is upregulated in brain tumorsJ Cereb Blood Flow Metab19981855005099591842
   PubMed Web of Science ®Google Scholar
• GalldiksNKrachtLWBurghausLUse of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomasEur J Nucl Med Mol Imaging200633551652416450140
   PubMed Web of Science ®Google Scholar
• WyssMHoferSBruehlmeierMEarly metabolic responses in temozolomide treated low-grade glioma patientsJ Neurooncol2009951879319381442
   PubMed Web of Science ®Google Scholar
• GalldiksNKrachtLWBurghausLPatient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastomaMol Imaging201091404620128997
   PubMed Web of Science ®Google Scholar
• JagerPLVaalburgWPruimJde VriesEGLangenKJPiersDARadiolabeled amino acids: basic aspects and clinical applications in oncologyJ Nucl Med200142343244511337520
   PubMed Web of Science ®Google Scholar
• BergmannRPietzschJFuechtnerF3-O-methyl-6-18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitroJ Nucl Med200445122116212215585490
   PubMed Web of Science ®Google Scholar
• UllrichRTKrachtLWJacobsAHNeuroimaging in patients with gliomasSemin Neurol200828448449418843576
   PubMed Web of Science ®Google Scholar
• WeberWAWesterHJGrosuALO-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative studyEur J Nucl Med200027554254910853810
   PubMedGoogle Scholar
• BechererAKaranikasGSzabóMBrain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionineEur J Nucl Med Mol Imaging200330111561156714579097
   PubMed Web of Science ®Google Scholar
• HerholzKHölzerTBauerB11C-methionine PET for differential diagnosis of low-grade gliomasNeurology1998505131613229595980
   PubMed Web of Science ®Google Scholar
• HustinxRPourdehnadMKaschtenBAlaviAPET imaging for differentiating recurrent brain tumor from radiation necrosisRadiol Clin North Am2005431354715693646
   PubMed Web of Science ®Google Scholar
• EricsonKLiljaABergströmMPositron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga] EDTA in supratentorial tumorsJ Comput Assist Tomogr1985946836893926834
   PubMed Web of Science ®Google Scholar
• OgawaTInugamiAHatazawaJClinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionineAJNR Am J Neuroradiol19961723453538938309
   PubMed Web of Science ®Google Scholar
• ChangCCKuwanaNItoSYokoyamaTKannoHYamamotoICerebral haemodynamics in patients with hydrocephalus after subarachnoid haemorrhage due to ruptured aneurysmEur J Nucl Med Mol Imaging200330112312612483419
   PubMed Web of Science ®Google Scholar
• De WitteOGoldbergIWiklerDPositron emission tomography with injection of methionine as a prognostic factor in gliomaJ Neurosurg200195574675011702862
   PubMed Web of Science ®Google Scholar
• RibomDErikssonAHartmanMPositron emission tomography (11)C-methionine and survival in patients with low-grade gliomasCancer20019261541154911745233
   PubMed Web of Science ®Google Scholar
• KaschtenBStevenaertASadzotBPreoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionineJ Nucl Med19983957787859591574
   PubMed Web of Science ®Google Scholar
• SasakiMKuwabaraYYoshidaTCarbon-11-methionine PET in focal cortical dysplasia: a comparison with fluorine-18-FDG PET and technetium-99m-ECD SPECTJ Nucl Med19983969749779627328
   PubMed Web of Science ®Google Scholar
• BustanyPChatelMDerlonJMBrain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-L-MethionineJ Neurooncol1986343974043485705
   PubMed Web of Science ®Google Scholar
• UllrichRTKrachtLBrunnAMethyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with gliomaJ Nucl Med200950121962196819910435
   PubMed Web of Science ®Google Scholar
• YamaneTSakamotoSSendaMClinical impact of (11)C-methionine PET on expected management of patients with brain neoplasmEur J Nucl Med Mol Imaging201037468569019915838
   PubMed Web of Science ®Google Scholar
• SpaethNWyssMTWeberBUptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrenceJ Nucl Med200445111931193815534065
   PubMed Web of Science ®Google Scholar
• ChenWSilvermanDHDelaloyeS18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracyJ Nucl Med200647690491116741298
   PubMed Web of Science ®Google Scholar
• PauleitDFloethFHamacherKO-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomasBrain2005128Pt 367868715689365
   PubMed Web of Science ®Google Scholar
• RachingerWGoetzCPöpperlGPositron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomasNeurosurgery2005573505511 discussion 505–51116145529
   PubMed Web of Science ®Google Scholar
• FloethFWPauleitDWittsackHJMultimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopyJ Neurosurg2005102231832715739561
   PubMed Web of Science ®Google Scholar
• RaseyJSGriersonJRWiensLWKolbPDSchwartzJLValidation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cellsJ Nucl Med20024391210121712215561
   PubMed Web of Science ®Google Scholar
• ShieldsAFGriersonJRDohmenBMImaging proliferation in vivo with [F-18]FLT and positron emission tomographyNat Med1998411133413369809561
   PubMed Web of Science ®Google Scholar
• BarthelHCleijMCCollingridgeDR3′-deoxy-3′-[18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomographyCancer Res200363133791379812839975
   PubMed Web of Science ®Google Scholar
• ChenWCloughesyTKamdarNImaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDGJ Nucl Med200546694595215937304
   PubMed Web of Science ®Google Scholar
• Munch-PetersenBCloosLJensenHKTyrstedGHuman thymidine kinase 1. Regulation in normal and malignant cellsAdv Enzyme Regul19953569897572355
   PubMedGoogle Scholar
• HatakeyamaTKawaiNNishiyamaY11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed gliomaEur J Nucl Med Mol Imaging200835112009201718542957
   PubMed Web of Science ®Google Scholar
• JacobsAHThomasAKrachtLW18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumorsJ Nucl Med200546121948195816330557
   PubMed Web of Science ®Google Scholar
• ChenWDelaloyeSSilvermanDHPredicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot studyJ Clin Oncol200725304714472117947718
   PubMed Web of Science ®Google Scholar
• SchwarzenbergJCzerninJCloughesyTF3′-deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumabJ Nucl Med2012531293622159180
   PubMed Web of Science ®Google Scholar
• HicklinDJEllisLMRole of the vascular endothelial growth factor pathway in tumor growth and angiogenesisJ Clin Oncol20052351011102715585754
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJNovotnyWBevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochem Biophys Res Commun2005333232833515961063
   PubMed Web of Science ®Google Scholar
• RaseyJSKohWJEvansMLQuantifying regional hypoxia in human tumors with positron emission tomography of [18F] fluoromisonidazole: a pretherapy study of 37 patientsInt J Radiat Oncol Biol Phys19963624174288892467
   PubMed Web of Science ®Google Scholar
• BrownJMTherapeutic targets in radiotherapyInt J Radiat Oncol Biol Phys200149231932611173124
   PubMed Web of Science ®Google Scholar
• SzetoMDChakrabortyGHadleyJQuantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomasCancer Res200969104502450919366800
   PubMed Web of Science ®Google Scholar
• CherLMMuroneCLawrentschukNCorrelation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studiesJ Nucl Med200647341041816513609
   PubMed Web of Science ®Google Scholar
• SpenceAMMuziMSwansonKRRegional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survivalClin Cancer Res20081492623263018451225
   PubMed Web of Science ®Google Scholar
• PaleologosTSDorwardNLWadleyJPThomasDGClinical validation of true frameless stereotactic biopsy: analysis of the first 125 consecutive casesNeurosurgery2001494830835 discussion 835–83711564243
   PubMed Web of Science ®Google Scholar
• RobbinsPDYuLLLeeMStereotactic biopsy of 100 intracerebral lesions at Sir Charles Gairdner HospitalPathology19942644104137892040
   PubMed Web of Science ®Google Scholar
• SanaiNEmerging operative strategies in neurosurgical oncologyCurr Opin Neurol201225675676623160424
   PubMed Web of Science ®Google Scholar
• TanakaSLouisDNCurryWTBatchelorTTDietrichJDiagnostic and therapeutic avenues for glioblastoma: no longer a dead end?Nat Rev Clin Oncol2013101142623183634
   PubMed Web of Science ®Google Scholar
• GilbertMRRecurrent glioblastoma: a fresh look at current therapies and emerging novel approachesSemin Oncol201138Suppl 4S21S3322078645
   PubMed Web of Science ®Google Scholar
• WellerMWickWHegiMEStuppRTabatabaiGShould biomarkers be used to design personalized medicine for the treatment of glioblastoma?Future Oncol2010691407141420919826
   PubMed Web of Science ®Google Scholar
• KelesGEAndersonBBergerMSThe effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphereSurg Neurol199952437137910555843
   PubMedGoogle Scholar
• PopeWBSayreJPerlinaAVillablancaJPMischelPSCloughesyTFMR imaging correlates of survival in patients with high-grade gliomasAJNR Am J Neuroradiol200526102466247416286386
   PubMed Web of Science ®Google Scholar
• LacroixMAbi-SaidDFourneyDRA multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJ Neurosurg200195219019811780887
   PubMed Web of Science ®Google Scholar
• KelesGEChangEFLambornKRVolumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytomaJ Neurosurg20061051344016871879
   PubMed Web of Science ®Google Scholar
• DuffauHCapelleLSichezJIntra-operative direct electrical stimulations of the central nervous system: the Salpetriere experience with 60 patientsActa Neurochir (Wien)1999141111157116710592115
   PubMed Web of Science ®Google Scholar
• DuffauHCapelleLSichezNIntraoperative mapping of the subcortical language pathways using direct stimulations. An anatomo-functional studyBrain2002125Pt 119921411834604
   PubMed Web of Science ®Google Scholar
• DuffauHCapelleLDenvilDUsefulness of intraoperative electrical subcortical mapping during surgery for low-grade gliomas located within eloquent brain regions: functional results in a consecutive series of 103 patientsJ Neurosurg200398476477812691401
   PubMed Web of Science ®Google Scholar
• LeeSKDiffusion tensor and perfusion imaging of brain tumors in high-field MR imagingNeuroimaging Clin N Am2012222123134 ix22548924
   PubMed Web of Science ®Google Scholar
• PriceSJGillardJHImaging biomarkers of brain tumour margin and tumour invasionBr J Radiol201184Spec 2S159S16722433826
   PubMed Web of Science ®Google Scholar
• SanaiNMirzadehZBergerMSFunctional outcome after language mapping for glioma resectionN Engl J Med20083581182718172171
   PubMed Web of Science ®Google Scholar
• SnydermanCHPantHCarrauRLPrevedelloDGardnerPKassamABWhat are the limits of endoscopic sinus surgery?: the expanded endonasal approach to the skull baseKeio J Med200958315216019826209
   PubMedGoogle Scholar
• McLaughlinNPrevedelloDMEnghJKellyDFKassamABEndoneurosurgical resection of intraventricular and intraparenchymal lesions using the port techniqueWorld Neurosurg201379Suppl 2S18.e1S18.e822381841
   PubMed Web of Science ®Google Scholar
• WalkerMDAlexanderEJrHuntWEEvaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trialJ Neurosurg1978493333343355604
   PubMed Web of Science ®Google Scholar
• WalkerMDStrikeTAShelineGEAn analysis of dose-effect relationship in the radiotherapy of malignant gliomasInt J Radiat Oncol Biol Phys197951017251731231022
   PubMed Web of Science ®Google Scholar
• ShelineGERadiotherapy for high grade gliomasInt J Radiat Oncol Biol Phys19901847938032182578
   PubMed Web of Science ®Google Scholar
• HochbergFHPruittAAssumptions in the radiotherapy of glioblastomaNeurology19803099079116252514
   PubMed Web of Science ®Google Scholar
• WallnerKEGalicichJHKrolGArbitEMalkinMGPatterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytomaInt J Radiat Oncol Biol Phys1989166140514092542195
   PubMed Web of Science ®Google Scholar
• ChoucairAKLevinVAGutinPHDevelopment of multiple lesions during radiation therapy and chemotherapy in patients with gliomasJ Neurosurg19866556546583021931
   PubMed Web of Science ®Google Scholar
• Ten HakenRKThorntonAFJrSandlerHMA quantitative assessment of the addition of MRI to CT-based, 3-D treatment planning of brain tumorsRadiother Oncol19922521211331332134
   PubMed Web of Science ®Google Scholar
• GlatsteinELichterASFraassBAKellyBAvan de GeijnJThe imaging revolution and radiation oncology: use of CT, ultrasound, and NMR for localization, treatment planning and treatment deliveryInt J Radiat Oncol Biol Phys19851122993143882642
   PubMed Web of Science ®Google Scholar
• GrossMWWeberWAFeldmannHJBartensteinPSchwaigerMMollsMThe value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomasInt J Radiat Oncol Biol Phys19984159899959719107
   PubMed Web of Science ®Google Scholar
• DouglasJGStelzerKJMankoffDA[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failureInt J Radiat Oncol Biol Phys200664388689116242251
   PubMed Web of Science ®Google Scholar
• NarayanaAYamadaJBerrySIntensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric resultsInt J Radiat Oncol Biol Phys200664389289716458777
   PubMed Web of Science ®Google Scholar
• ChanJLLeeSWFraassBASurvival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapyJ Clin Oncol20022061635164211896114
   PubMed Web of Science ®Google Scholar
• ShrieveDCAlexanderE3rdBlackPMTreatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcomeJ Neurosurg1999901727710413158
   PubMed Web of Science ®Google Scholar
• PriscoFEWeltmanEde HanriotRMBrandtRARadiosurgical boost for primary high-grade gliomasJ Neurooncol200257215116012125977
   PubMed Web of Science ®Google Scholar
• NwokediECDiBiaseSJJabbourSHermanJAminPChinLSGamma knife stereotactic radiosurgery for patients with glioblastoma multiformeNeurosurgery20025014146 discussion 46–4711844233
   PubMed Web of Science ®Google Scholar
• MehtaMPMasciopintoJRozentalJStereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantageInt J Radiat Oncol Biol Phys19943035415497928484
   PubMed Web of Science ®Google Scholar
• KogaTMaruyamaKTanakaMExtended field stereotactic radiosurgery for recurrent glioblastomaCancer2012118174193420022180028
   PubMed Web of Science ®Google Scholar
• KondziolkaDFlickingerJCBissonetteDJBozikMLunsfordLDSurvival benefit of stereotactic radiosurgery for patients with malignant glial neoplasmsNeurosurgery101997414776783 discussion 783–7759316038
   PubMed Web of Science ®Google Scholar
• SouhamiLSeiferheldWBrachmanDRandomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocolInt J Radiat Oncol Biol Phys200460385386015465203
   PubMed Web of Science ®Google Scholar
• ParkKJKanoHIyerASalvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control studyJ Neurooncol2012107232333322057917
   PubMed Web of Science ®Google Scholar
• KogaTShinMSaitoNRole of gamma knife radiosurgery in neurosurgery: past and future perspectivesNeurol Med Chir (Tokyo)201050973774820885108
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPvan den BentMJEuropean Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy GroupsNational Cancer Institute of Canada Clinical Trials GroupRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
   PubMed Web of Science ®Google Scholar
• StuppRHegiMEMasonWPEuropean Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology GroupsNational Cancer Institute of Canada Clinical Trials GroupEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol200910545946619269895
   PubMed Web of Science ®Google Scholar
• Erdem-EraslanLGravendeelLAde RooiJIntrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951J Clin Oncol201331332833623269986
   PubMed Web of Science ®Google Scholar
• WangYJiangTUnderstanding high grade glioma: molecular mechanism, therapy and comprehensive managementCancer Lett2013331213914623340179
   PubMed Web of Science ®Google Scholar
• Alliance for Clinical Trials in OncologyRadiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic GliomaClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2009 [updated November 7, 2013]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00887146. NLM identifier: NCT00887146Accessed February 5, 2014
   Google Scholar
• European Organisation for Research and Treatment of Cancer – EORTCRadiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic GliomaClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2008 [updated September 16, 2011]. Available from: http://clinicaltrials.gov/show/NCT00626990. NLM identifier: NCT00626990Accessed February 5, 2014
   Google Scholar
• WongETHessKRGleasonMJOutcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trialsJ Clin Oncol19991782572257810561324
   PubMed Web of Science ®Google Scholar
• LambornKRYungWKChangSMNorth American Brain Tumor ConsortiumProgression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasNeuro Oncol200810216217018356283
   PubMed Web of Science ®Google Scholar
• BallmanKVBucknerJCBrownPDThe relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeNeuro Oncol200791293817108063
   PubMed Web of Science ®Google Scholar
• GerstnerERBatchelorTTAntiangiogenic therapy for glioblastomaCancer J2012181455022290257
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAReardonDAThe addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastomaClin Cancer Res201117124119412421531816
   PubMed Web of Science ®Google Scholar
• HaslinghuisLMKrenningEPDe HerderWWReijsAEKwekkeboomDJSomatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancerJ Endocrinol Invest200124641542211434665
   PubMed Web of Science ®Google Scholar
• JainRKdi TomasoEDudaDGLoefflerJSSorensenAGBatchelorTTAngiogenesis in brain tumoursNat Rev Neurosci20078861062217643088
   PubMed Web of Science ®Google Scholar
• GuptaKRadotraBDBanerjeeAKNijhawanRQuantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumorsAnal Quant Cytol Histol200426422322915457675
   PubMed Web of Science ®Google Scholar
• NamDHParkKSuhYLKimJHExpression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significanceOncol Rep200411486386915010886
   PubMed Web of Science ®Google Scholar
• TakanoSTsuboiKMatsumuraANoseTAnti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenograftsNeuro Oncol2003511712626127
   PubMed Web of Science ®Google Scholar
• CohenMHShenYLKeeganPPazdurRFDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma MultiformeOncologist200914111131113819897538
   PubMed Web of Science ®Google Scholar
• LaiATranANghiemphuPLPhase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiformeJ Clin Oncol201129214214821135282
   PubMed Web of Science ®Google Scholar
• ReardonDATurnerSPetersKBA review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastomaJ Natl Compr Canc Netw20119441442721464146
   PubMed Web of Science ®Google Scholar
• NordenADDrappatzJMuzikanskyAAn exploratory survival analysis of anti-angiogenic therapy for recurrent malignant gliomaJ Neurooncol200992214915519043778
   PubMed Web of Science ®Google Scholar
• BealKAbreyLEGutinPHAntiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approachesRadiat Oncol20116221214925
   PubMed Web of Science ®Google Scholar
• KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
   PubMed Web of Science ®Google Scholar
• KhasrawMLassmanABAdvances in the treatment of malignant gliomasCurr Oncol Rep2010121263320425605
   PubMed Web of Science ®Google Scholar
• KunnakkatSNarayanaABevacizumab in the treatment of high-grade gliomas: an overviewAngiogenesis201114442343021858651
   PubMed Web of Science ®Google Scholar
• Memorial Sloan-Kettering Cancer CenterHypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant GliomaClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated December 17, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT01392209. NLM identifier: NCT01392209Accessed February 5, 2014
   Google Scholar
• CabreraARCuneoKCVredenburghJJSampsonJHKirkpatrickJPStereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiformeJ Natl Compr Canc Netw201210669569922679114
   PubMed Web of Science ®Google Scholar
• CloughseyTWickWMasonWPhase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly diagnosed glioblastoma: Final progression-free survival and preliminary overall survival results from AVAglioNeurology201380Meeting Abstracts 1PL02.002
   Google Scholar
• GilbertMRDignamJWonMRTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM)J Clin Oncol201331Suppl abstr 1
   Google Scholar
• van den BentMJChinotOBoogerdWSecond-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972Ann Oncol200314459960212649108
   PubMed Web of Science ®Google Scholar
• ReardonDAGalanisEDeGrootJFClinical trial end points for high-grade glioma: the evolving landscapeNeuro Oncol201113335336121310734
   PubMed Web of Science ®Google Scholar
• AbreyLELouisDNPaleologosNOligodendroglioma Study GroupSurvey of treatment recommendations for anaplastic oligodendrogliomaNeuro Oncol20079331431817435180
   PubMed Web of Science ®Google Scholar
• DeAngelisLMAnaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]J Clin Oncol200927355861586219901101
   PubMed Web of Science ®Google Scholar
• MurrellJBoardRThe use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questionsCancer Treat Rev201339883383823845462
   PubMed Web of Science ®Google Scholar
• SampsonJHAldapeKDArcherGEGreater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaNeuro Oncol201113332433321149254
   PubMed Web of Science ®Google Scholar
• WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295
   PubMed Web of Science ®Google Scholar